# ZEN-3694 with platinum chemotherapy in NUT carcinoma (NCI phase 1/2)

Source: https://onco.cc/trials/zen-3694-platinum-nut/  
OnCo record `zen-3694-platinum-nut` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

The main open trial for NUT carcinoma, pairing a BET inhibitor that attacks the BRD4-NUT fusion directly with the platinum chemotherapy patients would otherwise receive alone.

## Summary

NUT carcinoma is driven by a fusion of NUTM1 to BRD4 or another BET protein, so BET bromodomain inhibitors are its most rational drugs; single agents produced responses but not durable ones. This National Cancer Institute study tests ZEN003694 with platinum-based chemotherapy in advanced NUT carcinoma, with a dose-finding phase 1 leading into phase 2. It is recruiting.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: owner-request
- Registry id: NCT05019716
- Phase: 1/2
- Setting: Advanced, metastatic or unresectable NUT carcinoma: the BET bromodomain inhibitor ZEN003694 added to platinum-based chemotherapy; started July 2022, 36 planned
- Sponsor: National Cancer Institute (NCI)
- Enrolled: 36

## Sources

- ClinicalTrials.gov NCT05019716: https://clinicaltrials.gov/study/NCT05019716

## Connected records

- cancers: [NUT carcinoma (midline carcinoma with NUTM1 rearrangement)](https://onco.cc/cancers/nut-carcinoma/)
- technologies: [Cytotoxic chemotherapy](https://onco.cc/technologies/cytotoxic-chemotherapy/), [Epigenetic drugs (HDAC, DNMT, EZH2, IDH, menin, BET)](https://onco.cc/technologies/epigenetic-drugs/)
- drugs: [Cisplatin](https://onco.cc/drugs/cisplatin/), [Etoposide](https://onco.cc/drugs/etoposide/), [ZEN-3694](https://onco.cc/drugs/zen-3694/)
- institutions: [National Cancer Institute (NIH)](https://onco.cc/institutions/nci/)

---
JSON: https://onco.cc/api/v1/entities/zen-3694-platinum-nut.json